Pharmacokinetics of Oseltamivir and Oseltamivir Carboxylate in Critically I ll Patients Receiving Continuous Venovenous Hemodialysis and/or Extracorporeal Membrane Oxygenation

View Full Paper

Ask AI

Bookmark

Share

Key Points

This study aims to assess the pharmacokinetics of oseltamivir and its active metabolite in critically ill patients undergoing specific therapies.
Prospective, open-label pharmacokinetic study conducted in intensive care units.
Thirteen patients aged 13 and older receiving oseltamivir while on continuous venovenous hemodialysis (CVVHD) and/or ECMO.
Blood, urine, and effluent samples were collected to evaluate drug concentrations at specified intervals.
Median maximum plasma concentration for oseltamivir was 83.4 ng/ml with AUC(0-12) of 216 ng•hour/ml.
Oseltamivir carboxylate showed a median peak concentration of 2000 ng/ml and AUC(0-12) of 21,500 ng•hour/ml.
CVVHD resulted in a mean clearance of 33.8 ml/min for oseltamivir and 50.2 ml/min for oseltamivir carboxylate.

We only have this paper's title and publication details.

Prospective study examines oseltamivir pharmacokinetics in critically ill patients, suggesting adjustments are needed for treatment.

No takes yet. Share an insight, caveat, or question.

Eyler et al. (2012) studied this question.

View Full Paper

Ask AI

Bookmark

Share